—The mean marginal bone level change reported was -0.03 millimeters after five years, which is extremely good, says Dr. AnnaKarin Lundgren, Head of Scientific Management at Astra Tech Dental.
The OsseoSpeed surface characteristics and properties have been reviewed in numerous published articles revealing positive bone response. Results from the extensive OsseoSpeed clinical study program show good functionality, and predictable and maintained marginal bone levels with a mean marginal bone level reduction of 0.3 mm. The maintained marginal bone levels are also confirmed in prospective studies with three and five year results. There is no significant dip in Implant Stability Quotient values traditionally seen at implants 2-6 weeks after installation. This is interpreted as a continuous gain in osseointegration and stability. Published data shows that the OsseoSpeed implant can be safely used with reported survival rate between 94.5% to 100%, including the use of immediate loading protocol even in the atrophic edentulous maxilla, in sinus lifted maxillary posterior jaw sites, immediate installation in extraction sockets and implants placed in atrophied mandibles close to the nerve.
OsseoSpeed is one of four key features of the Astra Tech BioManagement Complex™. The other three key features are Conical Seal Design™, Connective Contour™ and MicroThread™ each of them with more than 17 years of clinical experience and documentation.
New data available —a comparative study on marginal bone level maintenance in implant treated patients recently published
Astra Tech Implant System™ comes out as number one in a meta–analysis study on marginal bone level maintenance recently published early online by Clinical Implant Dentistry and Related Research1.
At the EAO meeting in Warsaw 2008, Astra Tech presented unique data on marginal bone level maintenance for the Astra Tech Implant System™ and challenged the current standard norm for implant treatment success. Today, a year after the Astra Tech challenge, this recently published scientific study by Dr. Laurell and co-worker, presents comparative data of the three implant systems fulfilling the set study inclusion criteria, whereof Astra Tech Implant System was one.
The purpose of the study was to compile and compare data on marginal bone level changes between loading and five years of function for all implant systems currently on the market.
To be included in this meta-analysis the implant systems, in addition to being on the market, should have a minimum of two published prospective studies presenting radiographic data of marginal bone level at baseline as well as after five years.
Astra Tech Implant System™ showed the best results with only -0,24 millimeters bone reduction after five years and had also the most consistent performance with a very limited variation between the mean values in the different studies.
—The result of this study proves that we were right when challenging the current standard norm. Hopefully the dental academic society will look into the data and set a new standard norm for implant treatment success. This will force less serious implant companies to perform and present solid, reliable documentation, all for the benefit of the patient. Only three implant systems met the criteria in the above study, but it is even more striking that 90% of all implant suppliers on the market are unable to show any clinical documentation2 whatsoever on their implant systems, says Dr. Björn Delin, Business Unit Director, Dental at Astra Tech in Sweden.
Expanded labeling claims for Astra Tech Implant System™ cleared by FDA in September 2009
The Astra Tech Implant System is designed to maintain the marginal bone support and is proven clinically to maintain marginal bone level (mean marginal bone reduction of only 0,3 mm over 5 years).
1. Laurell L, Lundgren D, Marginal bone level changes at dental implants after 5 years in function. A meta-analysis. Clin Impl Dent Rel Res 2009, early online
2. Jokstad 2009, Osseointegration and Dental Implants (chapter 1), Wiley-Blackwell
For further information, please contact:
Dr Björn Delin, Business Unit Director, Dental
Astra Tech AB, Sweden
Phone: +46 705 76 72 60
Kerstin Wettby, Head Market Communication, Dental
Astra Tech AB, Sweden
Phone: +46 705 16 32 02
About Astra Tech
Astra Tech AB, a subsidiary of the AstraZeneca group, develops, manufactures, markets dental implants and advanced disposable products for use within healthcare. The company develops products that enhance treatment results, simplify work for healthcare professionals and help cut healthcare costs.
Astra Tech’s headquarters and production facilities are located in Mölndal, Sweden. The company is represented globally by 16 subsidiaries and selected local partners. Astra Tech has a total of 2,100 employees worldwide. The company puts 5 percent of its revenues annually into research. Astra Tech’s revenues in 2008 totalled SEK 3,4 billion.